Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ IgG positive 87% Improvement Relative Risk HCQ for COVID-19  Goenka et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 962 patients in India Lower IgG positivity with HCQ (p=0.032) c19hcq.org Goenka et al., SSRN, October 2020 Favors HCQ Favors control

Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India

Goenka et al., SSRN, doi:10.2139/ssrn.3689618
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Study of SARS-CoV-2-IgG antibodies in 1122 health care workers in India finding 87% lower positives for adequate HCQ prophylaxis, 1.3% HCQ versus 12.3% for no HCQ prophylaxis.
Adequate prophylaxis is defined as 400mg 1/wk for >6 weeks.
risk of IgG positive, 87.2% lower, RR 0.13, p = 0.03, treatment 1 of 77 (1.3%), control 115 of 885 (13.0%), NNT 8.6, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Goenka et al., 24 Oct 2020, retrospective, India, preprint, 11 authors.
This PaperHCQAll
Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a metropolitan city from India
Mahesh Kumar, Goenka Dm, MD Shivaraj Afzalpurkar, MSc Mohuya Mukherjee, MD Surabhi Jajodia, Bhavik Bharat, Consultant, Shah Dnb, MD Ujjwayini Khan, MD Syamasis Bandyopadhyay, Dr Mahesh Kumar Goenka
Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a metropolitan city from India
Supplementary material Questionnaire for the study population This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3689618 P r e p r i n t n o t p e e r r e v i e w e d
References
Baggett, Keyes, Sporn, Gaeta, Prevalence of SARS-CoV-2 infection in residents of a large homeless shelter in Boston, JAMA
Brant-Zawadzki, Fridman, Robinson, Zahn, German et al., SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a single-center study
Chen, Tong, Wang, Huang, Yin et al., High SARS-CoV-2 Antibody Prevalence among Healthcare Workers Exposed to COVID-19 Patients, J Infect
Day, Covid-19: four-fifths of cases are asymptomatic, China figures indicate, BMJ
Eyre, Lumley, Donnell, Campbell, Sims et al., Differential occupational risks to healthcare workers from SARS-CoV-2: A prospective observational study, medRxiv
Fujita, Kada, Kanai, Hata, Odagaki et al., the southern part of Kyoto city during the COVID-19 peri-pandemic period
Furukawa, Brooks, Sobel, Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic, Emerg Infect Dis
Gao, Tian, breakthrough: chloroquine phosphate has shown apparent efficacy in the treatment of covId-19 associated pneumonia in clinical studies, Biosci Trends
Garcia-Basteiro, Moncunill, Tortajada, Vidal, Guinovart et al., Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital, Nat Commun
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Harding, Broom, Broom, Aerosol generating procedures and infective risk to healthcare workers: SARS-CoV-2-the limits of the evidence, J Hosp Infec
Iversen, Bundgaard, Hasselbalch, Kristensen, Nielsen et al., Risk of COVID-19 in health-care workers in Denmark: an observational cohort study, Lancet Infect Dis
Korth, Wilde, Dolff, Anastasiou, Krawczyk et al., SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients, J Clin Virol
Lin, Liu, Zhang, Hu, Yang et al., Evaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak, medRxiv
Liu, Cheng, Xu, Yang, Zhu et al., Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross-sectional study, BMJ
Liu, Liu, Kou, Zheng, Ding et al., Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2, J Clin Microbiol
Mizumoto, Kagaya, Zarebski, Chowell, Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Eurosurveillance
Moscola, Sembajwe, Jarrett, Farber, Chang et al., Prevalence of SARS-CoV-2 antibodies in health care personnel in the New York City area, JAMA
Ng, Poon, Puar, Quah, Loh et al., COVID-19 and the risk to health care workers: a case report, Ann Intern Med
Okba, Müller, Wang, Geurtsvankessel, Corman, Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients, Emerg Infect Dis
Ou, Liu, Lei, Li, Mi et al., Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV, Nat Commun
Pallett, Rayment, Patel, Sa, Denny et al., Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study, Lancet Respir Med
Sharma, Batra, Kumar, Mishra, Singla et al., BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic, Allergol Immunopathol
Steensels, Oris, Coninx, Nuyens, Delforge et al., Hospital-wide SARS-CoV-2 antibody screening in 3056 staff in a tertiary center in Belgium, JAMA
Sutton, Fuchs, 'alton, Goffman, Universal screening for SARS-CoV-2 in women admitted for delivery, N Engl J Med
Theel, Harring, Hilgart, Granger, Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2, J Clin Microbiol
Woon, Lee, Chong, Ayub, Krishnabahawan et al., facilities designated for COVID-19 care
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zhao, Markensohn, Wollensak, Laterza, Testing for SARS-CoV-2: the day the world turned its attention to the clinical laboratory, Clin Transl Sci
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit